利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

30 条记录 (耗时 0.033 秒)

    Monkey monoclonal antibodies specific to human B7.1 and/or B7.2, primatized forms thereof, pharmaceutical compositions containing, and use thereof as immunosuppressants
    11.
    发明申请
    Monkey monoclonal antibodies specific to human B7.1 and/or B7.2, primatized forms thereof, pharmaceutical compositions containing, and use thereof as immunosuppressants 失效
    对人B7.1和/或B7.2特异性的猴单克隆抗体，其灵长类化合物，含有其的药物组合物及其作为免疫抑制剂的用途

    公开(公告)号：US20010024648A1

    公开(公告)日：2001-09-27

    申请号：US09758173

    申请日：2001-01-12

    申请人： IDEC Pharmaceuticals Corporation

    发明人： Darrell R. Anderson ,  Peter Brams ,  Nabil Hanna ,  William S. Shestowsky ,  Cheryl Heard

    IPC分类号： A61K039/395

    CPC分类号： C07K14/70532 ,  A61K38/00 ,  C07K16/2827

    摘要： The present invention relates to the identification of macaque antibodies to human B7.1 and B7.2 by screening of phage display libraries or monkey heterohybridomas obtained using B lymphocytes from B7.1 and/or B7.2 immunized monkeys. More specifically, the invention provides four monkey monoclonal antibodies 7B6, 16C10, 7C10 and 20C9 which inhibit the B7:CD28 pathway and thereby function as effective immunosuppressants. The invention further provides the complete DNA and amino acid sequences of the light and heavy chain of three primatized antibodies derived from those monkey monoclonal antibodies which bind B7.1 and possibly B7.2, primatized 7C10, primatized 7B6 and primatized 16C10. These primatized and monkey antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

    摘要翻译： 本发明涉及通过筛选使用B7.1和/或B7.2免疫的猴子的B淋巴细胞获得的噬菌体展示文库或猴杂合杂交瘤来鉴定人B7.1和B7.2的猕猴抗体。 更具体地，本发明提供四种抑制B7：CD28途径的猴单克隆抗体7B6,16C10,7C10和20C9，从而起到有效的免疫抑制剂的作用。 本发明进一步提供衍生自结合B7.1和可能B7.2，灵长类化7C10，灵长类化7B6和灵长类16C10的猴单克隆抗体的三种灵长类抗体轻链和重链的完整DNA和氨基酸序列。 这些灵长类和猴抗体可以用作特异性免疫抑制剂，例如用于治疗自身免疫性疾病和预防器官移植排斥。

    Compositions and methods for treating cancer using IGSF9 and LIV-1
    14.
    发明申请
    Compositions and methods for treating cancer using IGSF9 and LIV-1 审中-公开
    使用IGSF9和LIV-1治疗癌症的组合物和方法

    公开(公告)号：US20040258616A1

    公开(公告)日：2004-12-23

    申请号：US10764604

    申请日：2004-01-27

    申请人： IDEC Pharmaceuticals Corporation

    发明人： Karen McLachlan ,  Scott Glaser ,  Robert J. Peach ,  Tony Rowe

    IPC分类号： A61K051/00 ,  A61K039/395 ,  C07K016/46

    CPC分类号： C07K14/70503 ,  A61K51/1027 ,  A61K51/1045 ,  C07K14/47 ,  C07K16/2803 ,  C07K16/30 ,  C07K2319/30

    摘要： Human IGSF9 and LIV-1 polypeptides and DNA (RNA) encoding such polypeptides are disclosed. The disclosed polypeptides and/or polynucleotide are particularly useful generating antibodies, both modified and native, which bind IGSF9 or LIV-1. Also disclosed are pharmaceutical compositions and vaccines comprising the antibodies, polypeptides and polynucleotides of the invention. Also disclosed are methods for utilizing such polypeptides for identifying ligands, antagonists and agonists to said polypeptides. Finally, methods comprising the above-mentioned compositions are disclosed for the treatment, diagnosis, and/or prognosis of neoplastic disorders.

    摘要翻译： 公开了人IGSF9和LIV-1多肽和编码这种多肽的DNA（RNA）。 公开的多肽和/或多核苷酸是特别有用的，其产生结合IGSF9或LIV-1的经修饰和天然的抗体。 还公开了包含本发明的抗体，多肽和多核苷酸的药物组合物和疫苗。 还公开了利用这些多肽鉴定所述多肽的配体，拮抗剂和激动剂的方法。 最后，公开了包含上述组合物的方法用于肿瘤性疾病的治疗，诊断和/或预后。